<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2016.64038</article-id><article-id pub-id-type="publisher-id">ACM-19283</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20160400000_81874235.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  同型半胱氨酸及其与血栓闭塞性脉管炎发病机制研究进展
  Advance in Research on Pathogenesis of Homocysteine Associated Thromboangiitis Obliterans
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>曾</surname><given-names>德创</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>天资</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>右江民族医学院附属医院，广西 百色</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>11</day><month>10</month><year>2016</year></pub-date><volume>06</volume><issue>04</issue><fpage>202</fpage><lpage>206</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    血栓闭塞性脉管炎(TAO)发生和发展的确切原因仍不清楚，目前比较明确的机制包括与MTHFR、CBS相关的基因缺陷导致同型半胱氨酸，B6、B12缺乏，吸烟、感染等遗传和环境因素在TAO中扮演了重要的角色，本病并不一定是由一种发病机制单独起作用，而有可能是多因素联合作用的结果，及其相互关系仍需更多的研究予以验证。
    The exact causes of the occurrence and development of thromboangiitis obliterans (TAO) are still unclear. So far, the mechanisms include the deficiency of homocysteine, vitamin B6 and B12 caused by the gene defect related to Methylene Tetrahydrofolate Reductase (MTHFR) and Cysta-thionine-β-synthase (CBS), smoking, infection, heredity and environment factors; and they play an important role in TAO. It’s probably that the TAO is the result of multi-factors rather than caused by only one single mechanism. The mutual relation between the factors still requires more research to prove. 
  
 
</p></abstract><kwd-group><kwd>同型半胱氨酸，血栓闭塞性脉管炎，发病机理, Homocysteine</kwd><kwd> Thromboangiitis Obliterans</kwd><kwd> Pathogenesis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>同型半胱氨酸及其与血栓闭塞性脉管炎 发病机制研究进展<sup> </sup></title><p>曾德创，李天资<sup>*</sup></p><p>右江民族医学院附属医院，广西 百色</p><disp-formula id="hanspub.19283-formula16"><graphic xlink:href="http://html.hanspub.org/file/13-1570290x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2016年11月17日；录用日期：2016年12月16日；发布日期：2016年12月19日</p><disp-formula id="hanspub.19283-formula17"><graphic xlink:href="http://html.hanspub.org/file/13-1570290x8_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>血栓闭塞性脉管炎(TAO)发生和发展的确切原因仍不清楚，目前比较明确的机制包括与MTHFR、CBS相关的基因缺陷导致同型半胱氨酸，B6、B12缺乏，吸烟、感染等遗传和环境因素在TAO中扮演了重要的角色，本病并不一定是由一种发病机制单独起作用，而有可能是多因素联合作用的结果，及其相互关系仍需更多的研究予以验证。</p><p>关键词 :同型半胱氨酸，血栓闭塞性脉管炎，发病机理</p><disp-formula id="hanspub.19283-formula18"><graphic xlink:href="http://html.hanspub.org/file/13-1570290x9_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s3"><title>1. 引言</title><p>同型半胱氨酸(Homocysteine, Hcy)或称为高半胱氨酸，是在体内不能合成的，又不属于必需氨基酸体的一种含硫基的氨基酸，Hcy在体内由甲硫氨酸转甲基后生成，是甲硫氨酸的中间代谢产物 [<xref ref-type="bibr" rid="hanspub.19283-ref1">1</xref>] 。研究表明，高同型半胱氨酸血症(hyperhomocysteinemia, HHCY)在血栓闭塞性脉管炎(Thromboangiitis obliterans, TAO)、冠心病(Coronary heart disease, CHD)、脑血管病(Cerebrovascular disease)和血栓形成(thrombosis)等慢性血管性疾病的发生发展中起重要作用，成为独立的危险因素之一 [<xref ref-type="bibr" rid="hanspub.19283-ref2">2</xref>] 。现就HHCY与TAO的研究进展综述如下。</p></sec><sec id="s4"><title>2. HHCY</title><p>血液中Hcy异常增高者称为HHCY，Hcy升高会造成人体甲基化和抗氧化能力减弱，同时加剧血管老化和粥样动脉硬化形成 [<xref ref-type="bibr" rid="hanspub.19283-ref3">3</xref>] 。HHCY和高血压、高血糖、血脂紊乱成为慢性血管疾病，损害人体健康的四大杀手，已经引起高度重视 [<xref ref-type="bibr" rid="hanspub.19283-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.19283-ref5">5</xref>] 。1931年生物化学家文森特–迪维尼奥(Vincent du Vigneaud，美国)从膀胱结石中分离出Hcy物质，1932年命名为Hcy，1955年Vincent du Vigneaud获取诺贝尔化学奖 [<xref ref-type="bibr" rid="hanspub.19283-ref6">6</xref>] 。Hcy包括同型半胱氨酸、双硫半胱氨酸和混和半胱氨酸，其大部分与血浆蛋白质结合存在，只有小部分(≤25%)的Hcy游离存在 [<xref ref-type="bibr" rid="hanspub.19283-ref7">7</xref>] 。1962年，Carson和Neil发现胱硫醚尿症(Cystathioninuria)是一种遗传性疾病，与同型半胱氨酸尿症关系密切，1964年Harvey Mndd等证明HHCY的病因与胱硫醚β合成酶(Cystathionine-β-synthase, CBS)的缺失及其Hcy代谢紊乱有关 [<xref ref-type="bibr" rid="hanspub.19283-ref8">8</xref>] 。Mccully于1969年从遗传性同型半胱氨酸尿症(Genetic Homocysteine Enuresis, GHE)死亡儿童尸检中发现，GHE患者有HHCY，同时患者早期就有全身动脉粥样硬化(Atherosclerosis, AS)和血栓形成(Phlebothrombosis)，由此提出HHCY或许成为导致动脉粥样硬化性血管性疾病的假说 [<xref ref-type="bibr" rid="hanspub.19283-ref9">9</xref>] 。四氢叶酸是体内转移“-碳基团”，包括甲基(-CH3)、甲酰基(-CHO)、甲烯基(-CH2)、次甲基(-CH)及羟甲基(-CH2OH)等的辅酶作用，亚甲基四氢叶酸还原酶(Methylene Tetrahydrofolate Reductase, MTHFR)在机体代谢中的主要作用为在叶酸代谢通路中将5,10-亚甲基四氢叶酸转化为具有生物学功能的5-甲基四氢叶酸 [<xref ref-type="bibr" rid="hanspub.19283-ref10">10</xref>] 。1988年，Kaug等人研究发现MTHFR与Hcy代谢相关，5-甲基四氢叶酸进入甲基传递通路，通过Hcy的重新甲基化过程间接为DNA甲基化和蛋白质甲基化提供甲基并且使血液中的Hcy水平保持在一个较低的水平 [<xref ref-type="bibr" rid="hanspub.19283-ref11">11</xref>] 。叶酸的中间代谢产物，通过碳单位代谢为嘌呤环提供碳原子，在核苷酸合成过程中有重要的作用 [<xref ref-type="bibr" rid="hanspub.19283-ref12">12</xref>] 。Hcy是一种含巯基的氨基酸，主要来源于饮食摄取的蛋氨酸，是蛋氨酸和半胱氨酸代谢过程中一个重要的中间产物，其本身并不参加蛋白质的合成 [<xref ref-type="bibr" rid="hanspub.19283-ref13">13</xref>] 。Hcy在体内的代谢途经有两个：第一，一部分Hcy和甲基四氢叶酸在蛋氨酸合成酶的作用下，生成蛋氨酸和四氢叶酸，四氢叶酸在MTHFR的作用下生成甲基四氢叶酸；第二，一部分的Hcy通过转硫基途径，即Hcy与丝氨酸在CBS作用下形成胱硫醚，一些胱硫醚在胱硫醚裂解酶的作用下形成半胱氨酸，最后生成丙酮酸、硫酸和水，另一些胱硫醚则生成同型丝氨酸 [<xref ref-type="bibr" rid="hanspub.19283-ref14">14</xref>] 。Hcy的代谢途经出现故障，可导致Hcy在机体内蓄积而发生HHCY，升高的Hcy在氨基酰-tRNA合成酶的作用下，生成同型半胱氨酸硫内酯(Homocysteine thiolactone, HTL)，HTL是Hcy在氨基酰-tRNA合成酶编辑或校正过程中形成的反应产物，属一种环硫酯。常见的Hcy代谢故障为：CBS变异，将导致Hcy蓄积，并且该途径是不可逆的。还有MTHFR的变异，导致甲叉四氢叶酸不能转化成甲基四氢叶酸，使Hcy代谢中重要的辅酶或甲基的供体减少，也造成Hcy的蓄积等等 [<xref ref-type="bibr" rid="hanspub.19283-ref15">15</xref>] 。Hcy在体内由甲硫氨酸转甲基后生成，在维生素B6的参与，Hcy可在CBS和胱硫醚酶的催化下生成半胱氨酸，经巯基氧化结合生成Hcy，Hcy也可在叶酸和维生素B12的辅助作用下再甲基化重新合成甲硫氨酸，此过程需甲硫氨酸合成酶的催化，并且必须有N5-甲基四氢叶酸作为甲基的供体，后者是MTHFR催化而产生 [<xref ref-type="bibr" rid="hanspub.19283-ref16">16</xref>] 。MTHFR基因的缺陷将导致机体多个基础生化过程的紊乱，包括细胞周期调控、DNA复制、DNA以及蛋白质甲基化修饰等，并引发血管等多种疾病 [<xref ref-type="bibr" rid="hanspub.19283-ref17">17</xref>] 。</p></sec><sec id="s5"><title>3. TAO</title><p>血栓闭塞性脉管炎(Thromboangiitis obliterans, TAO)是一种病变始于机体远端的，发生于中小动脉的，累及邻近静脉和神经的进行性、节段性、非感染性性血管损害疾病，病变累及脉管全层，其病理变化主要是病变的血管出现继发腔内炎症细胞浸润性血栓、管腔闭塞和机化 [<xref ref-type="bibr" rid="hanspub.19283-ref18">18</xref>] 。目前认为，TAO患者携带一些易感遗传基因，并在吸烟，性激素代谢紊乱，或继发于急慢性感染所导致的自身免疫功能紊乱等有关 [<xref ref-type="bibr" rid="hanspub.19283-ref19">19</xref>] 。病变主要累及四肢的中小动脉，常见于下肢 [<xref ref-type="bibr" rid="hanspub.19283-ref20">20</xref>] 。TAO患者因患肢循环障碍肢体缺血引起的局部皮肤疮白、冰凉、麻木、胼胝感、针刺感或烧灼感等感觉障碍，并有局部疼痛，间歇性跛行，静息痛等症状，进而出现局部营养障碍包括皮肤干燥，光滑，水肿，毳毛脱落，皮肤出现水疱，瘀点，瘀斑，色素沉着，肢端发凉等，如致病因素不能排除，临床症状反复发作，局部组织因较长时间的缺氧缺血，出现坏死、机化和坏疽 [<xref ref-type="bibr" rid="hanspub.19283-ref21">21</xref>] 。坏死是以酶溶性变化为特点的活体内局部组织细胞的死亡。机化(Organization)是由新生的肉芽组织吸收取代坏死组织的过程。坏疽(Gangrene)是继发腐败菌感染，坏死组织经腐败菌分解产生硫化氢，硫化氢与血红蛋白中铁离子结合形成硫化铁，使坏死组织呈黑色 [<xref ref-type="bibr" rid="hanspub.19283-ref22">22</xref>] 。坏死的肢端不但不能恢复生命细胞代谢，还会不断释放有害物质威胁机体，产生严重后果，临床上为了保障患者生命不得不给患者截肢，因此过去本病致残高，随着医学科学的快速发展，诊疗手段、方法和技术正在不断提高，TAO的早期诊断率和临床治愈率正在逐年提高 [<xref ref-type="bibr" rid="hanspub.19283-ref23">23</xref>] 。迄今TAO发病机制尚不完全清楚，近20年来对Hcy与慢性血管疾病的相关关系做了大量研究，并得到许多的共识。研究发现，TAO患者出现免疫调节机能障碍，调节细胞的生理功能紊乱，影响其免疫系统调控，出现临床症状 [<xref ref-type="bibr" rid="hanspub.19283-ref24">24</xref>] 。</p></sec><sec id="s6"><title>4. HHCY与TAO</title><p>临床研究表明，HHCY可以直接或间接导致血管内皮细胞损伤，促进血管平滑肌细胞增殖，影响低密度脂蛋白的氧化，增强血小板功能，促进血栓形成 [<xref ref-type="bibr" rid="hanspub.19283-ref25">25</xref>] 。HHCY既可以促进血管平滑肌细胞的增殖和迁移，又可以促进内皮细胞的凋亡。低浓度Hcy可以促进细胞增殖而高浓度则抑制细胞增殖，甚至引起细胞的凋亡，而且Hcy对不同器官和组织中的血管平滑肌细胞的作用亦可能不同。但HHCY的致病机理还不十分清楚 [<xref ref-type="bibr" rid="hanspub.19283-ref26">26</xref>] 。引起Hcy代谢障碍的原因有遗传和环境营养两种因素。在遗传方面，1) 在HHCY患者中，HCY水平与TAO的临床症状和转归呈线性关系，即高水平HCY患者其临床症状重，预后欠佳；2) HHCY患者尸检病理发现动脉内膜纤维性斑块，弹力层破坏，疏松结缔组织增生，间质细胞部分溶解，线粒体破坏，呈剂量线性的关系；3) 升高的Hcy水平可明显影响患者血小板活化、凝血因子激活和内皮机能损伤，HHCY可以诱导内皮细胞产生和激活促凝血因子，促进纤溶酶激活物抑制剂(PAI)的表达，抑制组织型纤溶酶原激活剂(tPA)的结合和作用，促进血小板的聚集，从而引起和促进血栓形成；4) 编码MTHFR、CBS、甲硫氨酸合成酶的基因发生碱基突变或插入、缺失，引起相应的Hcy代谢酶的缺陷或活性下降，出现HHCY [<xref ref-type="bibr" rid="hanspub.19283-ref27">27</xref>] 。目前认为MTHFR的纯合子突变可能是产生HHCY并诱发TAO的一个重要危险因子，MTHFR的C677T有CC(野生型)、CT(杂和型)和TT(突变型)三个基因型，调查发现，在TAO患者中，携带C677T基因TT突变的比例比较高，并发现携带C677T基因TT突变的患者，其MTHFR酶活性比较低，血浆同型半胱氨酸水平异常增高，TAO的临床症状比较重。在营养方面，Hcy与丝氨酸在CBS催化下，生成胱硫醚，需要维生素B6为辅因子，Hcy在MTHFR催化下，生成蛋氨酸，需要维生素B12为辅因子，因此B6、B12缺乏，可出现HHCY，并影响机体正常代谢产生疾病。在环境方面，认为TAO的发生和发展与环境如吸烟、感染、免疫机能紊乱等因素的诱导和持续的炎症作用密切相关。因此认为防治HHCY型TAO应当从抑制同型半胱氨酸的生成，促进同型半胱氨酸代谢，对抗同型半胱氨酸的作用等三方面入手 [<xref ref-type="bibr" rid="hanspub.19283-ref28">28</xref>] 。</p><p>综上所述，TAO的发病机制复杂，目前比较明确的机制包括与MTHFR、CBS相关的基因缺陷导致同型半胱氨酸，B6、B12缺乏，吸烟、感染等遗传和环境因素在TAO中扮演了重要的角色，本病并不一定是由一种发病机制单独起作用，而有可能是多因素联合作用的结果，及其相互关系仍需更多的研究予以验证，基因、转录和蛋白质组中的致病机制和干预性研究或许可以发挥一定的优势。</p></sec><sec id="s7"><title>基金项目</title><p>国家自然科学基金(81060028)；广西重大专项基金(桂科重1598005-9，桂科攻1355005-3-7)；广西高等学校科学研究资助项目(KY2015YB230)；百色市学研究资助项目(百科计20141104, 20130106)。</p></sec><sec id="s8"><title>文章引用</title><p>曾德创,李天资. 同型半胱氨酸及其与血栓闭塞性脉管炎发病机制研究进展 Advance in Research on Pathogenesis of Homocysteine Associated Thromboangiitis Obliterans[J]. 临床医学进展, 2016, 06(04): 202-206. http://dx.doi.org/10.12677/ACM.2016.64038</p></sec><sec id="s9"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.19283-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Shankle, W.R., Hara, J., Barrentine, L.W., et al. (2016) Cerefolin NAC Therapy of Hyperhomocysteinemia Delays Cortical and White Matter Atrophy in Alzheimer’s Disease and Cerebrovascular Disease. Journal of Alzheimer’s Disease, 54, 1073-1084. https://doi.org/10.3233/JAD-160241</mixed-citation></ref><ref id="hanspub.19283-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Hrncic, D., Mikić, J., Rasic-Markovic, A., et al. (2016) Anxiety-Related Behavior in hyperhomocysteinemia Induced by Methionine Nutritional Overload in Rats: Role of the Brain Oxidative Stress. Canadian Journal of Physiology and Pharmacology, 94, 1074-1082. https://doi.org/10.1139/cjpp-2015-0581</mixed-citation></ref><ref id="hanspub.19283-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Hemanth Kumar, B., Dinesh Kumar, B. and Diwan, P.V. (2016) Hes-peridin, a Citrus Flavonoid, Protects against l-Methionine-Induced Hyperhomocysteinemia by Abrogation of Oxidative Stress, Endothelial Dysfunction and Neurotoxicity in Wistar Rats. Pharmaceutical Biology, 27, 1-10. https://doi.org/10.1080/13880209.2016.1231695</mixed-citation></ref><ref id="hanspub.19283-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Paul, R. and Borah, A. (2016) L-DOPA-Induced Hyperhomo-cysteinemia in Parkinson’s Disease: Elephant in the Room. Biochimica et Biophysica Acta, 1860, 1989-1997. https://doi.org/10.1016/j.bbagen.2016.06.018</mixed-citation></ref><ref id="hanspub.19283-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Gao, L., Kolanuvada, B., Naik, G., et al. (2016) Hyperhomocyste-inemia-Induced Upper Extremity Deep Vein Thrombosis and Pulmonary Embolism in a Patient with Methyltetrahy-drofolate Reductase Mutation: A Case Report and Literature Review. Blood Coagulation &amp; Fibrinolysis, 27, 720-723. https://doi.org/10.1097/MBC.0000000000000458</mixed-citation></ref><ref id="hanspub.19283-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Toda, N. and Okamura, T. (2016) Hyperhomocysteinemia Im-pairs Regional Blood Flow: Involvements of Endothelial and Neuronal Nitric Oxide. Pflügers Archiv, 468, 1517-1525. https://doi.org/10.1007/s00424-016-1849-y</mixed-citation></ref><ref id="hanspub.19283-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Naseri, M., Sarvari, G.R., Esmaeeli, M., et al. (2016) High Doses of Oral Folate and Sublingual Vitamin B12 in Dialysis Patients with Hyperhomocysteinemia. Journal of Renal Injury Prevention, 5, 134-139.  
https://doi.org/10.15171/jrip.2016.28</mixed-citation></ref><ref id="hanspub.19283-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Deminice, R., Cella, P.S., Padilha, C.S., et al. (2016) Creatine Supple-mentation Prevents Hyperhomocysteinemia, Oxidative Stress and Cancer-Induced Cachexia Progression in Walker-256 Tumor-Bearing Rats. Amino Acids, 48, 2015-2024. https://doi.org/10.1007/s00726-016-2172-9</mixed-citation></ref><ref id="hanspub.19283-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ibrahimagic, O.C., Smajlovic, D., Dostovic, Z., et al. (2016) Hyperhomocysteinemia and Its Treatment in Patients with Parkinson’s Disease. Materia Socio Medica, 28, 303-306. https://doi.org/10.5455/msm.2016.28.303-306</mixed-citation></ref><ref id="hanspub.19283-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Chung, Y.C., Kruyer, A., Yao, Y., et al. (2016) Hyperhomocysteinemia Exacerbates Alzheimer’s Disease Pathology by Way of the β-Amyloid Fibrinogen Interaction. Journal of Thrombosis and Haemostasis, 14, 1442-1452.  
https://doi.org/10.1111/jth.13340</mixed-citation></ref><ref id="hanspub.19283-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Korai, M., Kitazato, K.T., Tada Y., et al. (2016) Hyperhomocysteinemia Induced by Excessive Methionine Intake Promotes Rupture of Cerebral Aneurysms in Ovariectomized Rats. Journal of Neuroinflammation, 13, 165.  
https://doi.org/10.1186/s12974-016-0634-3</mixed-citation></ref><ref id="hanspub.19283-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Molina-López, J., Florea, D., Quintero-Osso, B., de la Cruzemail, A.P., Rodríguez-Elviraemail, M. and del Pozo, E.P. (2016) Pyridoxal-5’-Phosphate Deficiency Is Associated with Hyperhomocysteinemia Regardless of Antioxidant, Thiamine, Riboflavin, Cobalamine, and Folate Status in Critically Ill Patients. Clinical Nutrition, 35, 706-712.  
https://doi.org/10.1016/j.clnu.2015.04.022</mixed-citation></ref><ref id="hanspub.19283-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Hainsworth, A.H., Yeo, N.E., Weekman, E.M. and Wilcock, D.M. (2016) Homocysteine, Hyperhomocysteinemia and Vascular Contributions to Cognitive Impairment and Dementia (VCID). Biochimica et Biophysica Acta, 1862, 1008- 1017. https://doi.org/10.1016/j.bbadis.2015.11.015</mixed-citation></ref><ref id="hanspub.19283-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Bhanji, R.A., Ma, M., Bain, V.G. and Montano-Loza, A.J. (2016) Hyperhomocysteinemia Is Associated with Severity of Cir-rhosis and Negative Impact after Liver Transplantation. Liver International, 36, 696-704.  
https://doi.org/10.1111/liv.12979</mixed-citation></ref><ref id="hanspub.19283-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Veeranki, S., Gandhapudi, S.K. and Tyagi, S.C. (2016) Interactions of Hyper-homocysteinemia and T Cell Immunity in Causation of Hypertension. Canadian Journal of Physiology and Pharma-cology, 28, 1-8.  
https://doi.org/10.1139/cjpp-2015-0568</mixed-citation></ref><ref id="hanspub.19283-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Bhargava, S., Bhargava, M.S., Bhargava, E.K. and Srivastava, L.M. (2016) Hyperhomocysteinemia, MMPs and Cochlear Function: A Short Review. Indian Journal of Clinical Biochemistry, 31, 148-151.  
https://doi.org/10.1007/s12291-015-0505-1</mixed-citation></ref><ref id="hanspub.19283-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Bonetti, F., Brombo, G. and Zuliani, G. (2016) The Relationship be-tween Hyperhomocysteinemia and Neurodegeneration. Neurodegenerative Disease Management, 6, 133-145. https://doi.org/10.2217/nmt-2015-0008</mixed-citation></ref><ref id="hanspub.19283-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Kocak, B. and Ustun, E.D. (2016) Vasa Nervorum as the Source of Corkscrew Collaterals in Thromboangiitis Obliterans (Buerger’s Disease). European Journal of Vascular and Endo-vascular Surgery, 52, 508.  
https://doi.org/10.1016/j.ejvs.2016.07.017</mixed-citation></ref><ref id="hanspub.19283-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">刘焱喆, 王勤运, 王海涛, 等. 血栓闭塞性脉管炎治疗进展[J]. 现代生物医学进展, 2014, 14(27): 5397-5400.</mixed-citation></ref><ref id="hanspub.19283-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Rivera-Chavarría, I.J. and Brenes-Gutiérrez, J.D. (2016) Thrombo-angiitis Obliterans (Buerger’s Disease). Annals of Medicine and Surgery, 7, 79-82. https://doi.org/10.1016/j.amsu.2016.03.028</mixed-citation></ref><ref id="hanspub.19283-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Aszalos, C., Dongó, E., Farkas, Z., et al. (2016) Cerebral Manifesta-tions of Thromboangiitis Obliterans. Case Report. Orvosi Hetilap, 157, 1207-1211. https://doi.org/10.1556/650.2016.30476</mixed-citation></ref><ref id="hanspub.19283-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Rimar, D., Rozenbaum, M., Slobodin, G., Boulman, N., KaLy, L. and Rosner, I. (2016) Thromboangiitis Obliterans Overlapping with Atherosclerotic Occlusive Arterial Disease: Small Mesenteric Artery Involvement by Thromboangiitis Obliterans. Harefuah, 155, 41-44.</mixed-citation></ref><ref id="hanspub.19283-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Abyshov, N.S., Abdullaev, A.G., Zakirdzhaev, E.D., et al. (2016) The Results of Combined Surgical Treatment of Thromboangiitis Obliterans and Critical Lower Limb Ischemia Using Prolonged Epidural Analgesia and Autohemotherapy with Ozone. Khirurgiia, 45-50.</mixed-citation></ref><ref id="hanspub.19283-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">赵文光, 王征. 血栓闭塞性脉管炎的研究现状[J]. 中华普通外科杂志, 2002, 17(5): 319-320.</mixed-citation></ref><ref id="hanspub.19283-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Soni, C.V., Tyagi, S.C., Todnem, N.D., et al. (2016) Hyperhomocysteinemia Alters Sinoatrial and Atrioventricular Nodal Function: Role of Magnesium in Attenuating These Effects. Cell Biochemistry and Biophysics, 74, 59-65.  
https://doi.org/10.1007/s12013-015-0711-8</mixed-citation></ref><ref id="hanspub.19283-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Kolling, J., Scherer, E.B., Siebert, C., et al. (2016) Severe Hyperho-mocysteinemia Decreases Respiratory Enzyme and Na+-K+ ATPase Activities, and Leads to Mitochondrial Alterations in Rat Amygdala. Neurotoxicity Research, 29, 408-418. https://doi.org/10.1007/s12640-015-9587-z</mixed-citation></ref><ref id="hanspub.19283-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Van Dijk, S.C., Enneman, A.W., Swart, K.M., et al. (2016) Effect of Vitamin B12 and Folic Acid Supplementation on Biomarkers of Endothelial Function and Inflammation among Elderly Individuals with Hyperhomocysteinemia. Vascular Medicine, 21, 91-98. https://doi.org/10.1177/1358863X15622281</mixed-citation></ref><ref id="hanspub.19283-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Ventura, P., Venturelli, G., Marcacci, M., et al. (2016) Hyperhomocysteinemia and MTHFR C677T Polymorphism in Patients with Portal Vein Thrombosis Complicating Liver Cirrhosis. Thrombosis Research, 141, 189-195.  
https://doi.org/10.1016/j.thromres.2016.03.024</mixed-citation></ref></ref-list></back></article>